|
EP1236473A3
(de)
*
|
1992-04-03 |
2003-01-15 |
The Regents Of The University Of California |
Selbst zusammenbaubares system zur verabreichung von polynukleotiden
|
|
US5972883A
(en)
*
|
1993-03-16 |
1999-10-26 |
Yeda Research And Development Co. Ltd. |
Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
|
|
DE19536246A1
(de)
*
|
1994-09-30 |
1996-04-04 |
Juergen Dr Regenold |
Pharmazeutische Zusammensetzung
|
|
CA2167104A1
(en)
*
|
1995-01-17 |
1996-07-18 |
Joerg G.D. Birkmayer |
Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration
|
|
US6051429A
(en)
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
|
JPH10212241A
(ja)
*
|
1996-05-27 |
1998-08-11 |
Sumitomo Pharmaceut Co Ltd |
Ｂｄｎｆを安定に含有する製剤
|
|
IS4516A
(is)
|
1997-07-01 |
1999-01-02 |
Gizurarson Sveinbjörn |
Nýtt lyfjaform
|
|
FR2771929B1
(fr)
*
|
1997-12-09 |
2001-02-23 |
Biovector Therapeutics |
Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
|
|
AU757907B2
(en)
*
|
1998-09-03 |
2003-03-13 |
Neuren Pharmaceuticals Limited |
Neuroprotection
|
|
JP4854853B2
(ja)
|
1998-11-12 |
2012-01-18 |
ライフ テクノロジーズ コーポレーション |
トランスフェクション薬剤
|
|
DE69928563T2
(de)
*
|
1998-12-09 |
2006-07-27 |
Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville |
Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem
|
|
AU1261501A
(en)
*
|
1999-12-06 |
2001-06-18 |
Stanley L. Gore |
Compositions and methods for intranasal delivery of active agents to the brain
|
|
AU783208B2
(en)
*
|
1999-12-09 |
2005-10-06 |
Novartis Vaccines And Diagnostics, Inc. |
Method for administering a cytokine to the central nervous system and the lymphatic system
|
|
EP1602378A1
(de)
*
|
1999-12-09 |
2005-12-07 |
Chiron Corporation |
Verfahren zur Verabreichung von Wirkstoffen in das zentrale Nervensystem oder Lymphsystem
|
|
DE10004547A1
(de)
*
|
2000-02-02 |
2001-08-09 |
Liedtke Pharmed Gmbh |
Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe
|
|
US7084126B1
(en)
*
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
EP1370282A2
(de)
*
|
2000-10-13 |
2003-12-17 |
Chiron Corporation |
Methode zur behandlung ischämischer zustände die das zentrale nervensystem beeinflussen
|
|
US20030051728A1
(en)
|
2001-06-05 |
2003-03-20 |
Lloyd Peter M. |
Method and device for delivering a physiologically active compound
|
|
JP2005503425A
(ja)
|
2001-05-24 |
2005-02-03 |
アレックザ モレキュラー デリヴァリー コーポレイション |
所定の吸入ルートによる薬剤エステルの送出
|
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
|
AU2002363947A1
(en)
|
2001-11-21 |
2003-07-24 |
Alexza Molecular Delivery Corporation |
Delivery of caffeine through an inhalation route
|
|
US20040127409A1
(en)
*
|
2002-11-07 |
2004-07-01 |
Milkhaus Laboratory, Inc. |
Method of treatment of psychological conditions by administration of nerve growth factor
|
|
EP1599474B1
(de)
|
2003-03-04 |
2013-04-24 |
California Institute Of Technology |
Heterocyclische oligomere Verbindungen zur DNS-Erkennung
|
|
WO2004104490A1
(en)
|
2003-05-21 |
2004-12-02 |
Alexza Pharmaceuticals, Inc. |
Self-contained heating unit and drug-supply unit employing same
|
|
US9216161B2
(en)
|
2004-08-13 |
2015-12-22 |
Healthpartners Research Foundation |
Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
|
|
US7776312B2
(en)
|
2004-08-13 |
2010-08-17 |
Healthpartners Research Foundation |
Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
|
|
US7618615B2
(en)
|
2004-08-13 |
2009-11-17 |
Healthpartners Research Foundation |
Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
|
|
US20090136505A1
(en)
|
2005-02-23 |
2009-05-28 |
Johanna Bentz |
Intranasal Administration of Active Agents to the Central Nervous System
|
|
CU23317A1
(es)
|
2005-07-22 |
2008-10-22 |
Ct De Investigacia N Y Desarro |
Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
|
|
WO2007025249A2
(en)
*
|
2005-08-26 |
2007-03-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for treatment of headaches by administration of oxytocin
|
|
US8153604B2
(en)
|
2006-04-24 |
2012-04-10 |
Geron Corporation |
CNS-tumor treatment method and composition
|
|
EP2121088B1
(de)
|
2007-03-09 |
2016-07-13 |
Alexza Pharmaceuticals, Inc. |
Erhitzungseinheit zur verwendung in einer arzneimittelabgabevorrichtung
|
|
WO2008131059A2
(en)
*
|
2007-04-17 |
2008-10-30 |
Codman & Shurtleff, Inc. |
Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease
|
|
US8383865B2
(en)
|
2007-04-17 |
2013-02-26 |
Codman & Shurtleff, Inc. |
Curcumin derivatives
|
|
US9707274B2
(en)
|
2007-06-08 |
2017-07-18 |
Healthpartners Research & Education |
Methods for preventing and treating post-traumatic stress disorder (PTSD)
|
|
JP2010535198A
(ja)
*
|
2007-08-02 |
2010-11-18 |
ブッダ バイオファーマ オイ リミテッド |
コハク酸のコリン塩を含む鼻腔内投与用医薬品組成物
|
|
US7723515B1
(en)
|
2009-01-26 |
2010-05-25 |
Codman & Shurtleff, Inc. |
Methylene blue—curcumin analog for the treatment of alzheimer's disease
|
|
JP2014502953A
(ja)
*
|
2010-08-16 |
2014-02-06 |
ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク |
細胞透過性治療薬の鼻腔内送達
|
|
US8609088B2
(en)
|
2011-05-10 |
2013-12-17 |
Regents Of The University Of Minnesota |
Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
|
|
US8987199B2
(en)
|
2011-06-15 |
2015-03-24 |
Nerve Access, Inc. |
Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
|
|
DE102012015248A1
(de)
*
|
2012-08-05 |
2014-02-06 |
Naum Goldstein |
Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn
|
|
US10279012B2
(en)
|
2013-03-11 |
2019-05-07 |
Healthpartners Research & Education |
Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
|
|
SG11201509419QA
(en)
|
2013-05-15 |
2015-12-30 |
Univ Minnesota |
Adeno-associated virus mediated gene transfer to the central nervous system
|
|
US10314911B2
(en)
|
2014-04-08 |
2019-06-11 |
Healthpartners Research & Education |
Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
|
|
US20170027963A1
(en)
*
|
2014-04-10 |
2017-02-02 |
Patrick Crowley |
Delivery of non-steroidal agents to the brain via the nasal tract to treat neurological disorders
|
|
WO2016011203A1
(en)
|
2014-07-15 |
2016-01-21 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
|
PT3242676T
(pt)
|
2015-01-07 |
2023-12-06 |
TONIX Pharmaceuticals Holding Corp |
Formulações de ocitocina que contém magnésio e métodos de uso
|
|
SG10201912761UA
(en)
|
2016-04-15 |
2020-02-27 |
The Trustees Of The Univ Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
AU2018257778B2
(en)
|
2017-04-24 |
2022-02-17 |
Cocrystal Pharma, Inc. |
Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
|
|
JP2020528898A
(ja)
|
2017-07-27 |
2020-10-01 |
ローカス アイピー カンパニー、エルエルシー |
医薬品、サプリメント及び摂取物質のバイオアベイラビリティを増進する組成物
|
|
EP3684938A1
(de)
|
2017-09-22 |
2020-07-29 |
The Trustees of the University of Pennsylvania |
Gentherapie zur behandlung von mukopolysaccharidose typ ii
|
|
CA3106556A1
(en)
|
2018-07-27 |
2020-01-30 |
Cocrystal Pharma, Inc. |
Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
|
|
WO2020055858A1
(en)
|
2018-09-10 |
2020-03-19 |
Cocrystal Pharma, Inc. |
Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
|
|
BR112021007275A2
(pt)
|
2018-10-17 |
2021-07-20 |
Cocrystal Pharma, Inc. |
combinações de inibidores de replicação de vírus da influenza
|
|
CA3118918A1
(en)
*
|
2018-11-05 |
2020-05-14 |
Rush University Medical Center |
Nasal delivery of low-dose aspirin for the treatment of neurodegenerative and lysosomal storage diseases
|
|
WO2020112716A1
(en)
|
2018-11-26 |
2020-06-04 |
Cocrystal Pharma, Inc. |
Inhibitors of influenza virus replication
|
|
BR112022002565A2
(pt)
*
|
2019-08-10 |
2022-05-03 |
Locus Ip Co Llc |
Distribuição olfativa de compostos terapêuticos ao sistema nervoso central
|
|
US20230151034A1
(en)
|
2020-03-17 |
2023-05-18 |
Cocrystal Pharma, Inc. |
Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
|
|
IL297069A
(en)
|
2020-04-10 |
2022-12-01 |
Cocrystal Pharma Inc |
Replication inhibitors of norovirus and corona virus
|
|
IL310394A
(en)
|
2021-08-03 |
2024-03-01 |
Cocrystal Pharma Inc |
Corona virus inhibitors
|